SantoSolve, a biopharmaceutical company focused on developing novel pain therapies today announced positive results from its Phase II study of 2PX, the company’s topical analgesic, in patients with osteoarthritis (OA). The study, a multi-center, double-blind, placebo-controlled Phase II trial met its pre-specified primary endpoint: reduction in pain from baseline to study week 4 (p=0.038). The study demonstrated a 35% reduction in pain from baseline after 4 weeks of twice-daily administration of 2PX, as compared to a 21% reduction in the control group. The study evaluated 84 patients enrolled at study sites in Norway. The study was designed as a two-arm, 4 + 4 week cross-over trial. During the trial 2PX or placebo was self-administered twice daily with a proprietary applicator to the site of pain. Read full press release below.
